Sanofi Consumer Healthcare India Limited announced robust financial results for the fourth quarter and the full year ending December 31, 2025. The company reported a 21% growth in FY’25 revenue, reaching ₹8,784 million, with Net Profit rising 33% year-on-year to ₹2,401 million. The Board also approved a final dividend of ₹75 per share for the fiscal year.
FY 2025 and Q4 Financial Highlights
Sanofi Consumer Healthcare India Limited (SCHIL) released its financial outcomes for the period ending December 31, 2025, showcasing sustained growth momentum across its business segments. The announcement confirms that the Board of Directors approved these results during their meeting on Wednesday, February 25, 2026.
Full Year Performance (FY ’25)
- Revenue reached ₹8,784 million, marking a significant growth of 21% over the previous year.
- Profit After Tax (PAT) saw an increase of 33% year-on-year, totaling ₹2,401 million, attributed to disciplined cost management.
- Domestic Sales grew by 7%.
- Export Sales demonstrated exceptional growth of 158% (noted as being due to a low base).
- A final dividend of ₹75 per share was declared for the year.
Fourth Quarter Performance (Q4 ’25 vs. Y-o-Y)
- Revenue grew by an impressive 47%, totaling ₹2,510 million.
- Net Profit (PAT) increased by 50% year-on-year, reaching ₹665 million.
- Domestic Sales were up 23%, bolstered by the relaunch of previously recalled products.
- Export Sales grew by 9.3x due to a low base comparison.
Management Commentary on Performance
Himanshu Bakshi, Managing Director of SCHIL, commented that the quarter’s performance emphasizes the strength of the core portfolio and the disciplined execution of the growth strategy. He noted healthy double-digit growth in the domestic business complemented by strong export contributions.
Amit Jain, Chairman of Sanofi Consumer Healthcare India Limited, stated that the full-year results reflect the strength of the strategy and disciplined execution. He highlighted that the strong financial performance enables the company to reward shareholders with the healthy ₹75 dividend per share.
About Sanofi Consumer Healthcare India Limited
SCHIL emerged as a distinct legal entity following its demerger from Sanofi India Limited on June 1, 2024, now operating independently with a dedicated focus on the Consumer Healthcare sector. The company is a leading player leveraging global experience to enhance wellbeing through key brands such as Allegra®, DePURA®, Avil® and Combiflam®, focusing on Allergy, Digestive Wellness, Pain Care, and Multivitamins.
Source: BSE
